Company	Price	Valuation					Profitability					Cash & leverage					Quality				Rating
		P/E	P/B	P/S	EV / EBITDA	DCF upside	Gross margin	Operating margin	Net margin	ROE	ROIC	FCF yield	Debt / equity	Net debt / EBITDA	Interest coverage	Current ratio	Dividend yield	Piotroski (0-9)	Altman Z	Rating score (1-5)
SLSthis companySELLAS Life Sciences Group, Inc.	$7.90	-15.08×	5.8×	0×	-12.67×	-92.7%	0.0%	0.0%	0.0%	-37.9%	-39.3%	-6.9%	0.01×	2.64×	0×	10.72×	0.0%	2	131.65	2	C
AVBPArriVent BioPharma, Inc.	$13.65	-4.66×	2.52×	0×	-4.38×	-92.2%	0.0%	0.0%	0.0%	-54.1%	-57.8%	-20.8%	0×	0.27×	0×	12.83×	0.0%	2	12.15	2	C+
CBIOCrescent Biopharma, Inc.	$14.11	-0.8×	0.61×	11.39×	0.59×	61.0%	100.0%	-1407.5%	-1419.6%	-75.8%	-74.6%	-117.0%	0.01×	1.41×	-69.85×	6.56×	0.0%	3	11.24	2	C+
CCCCC4 Therapeutics, Inc.	$3.10	-1.5×	0.62×	4.4×	-1.4×	-187.2%	77.8%	-290.7%	-292.1%	-40.9%	-31.4%	-62.7%	0.23×	0.14×	0×	7.81×	0.0%	3	-1.03	2	C
IDYAIDEAYA Biosciences, Inc.	$31.45	-27.01×	2.99×	13.99×	-19.22×	-438.0%	-43.9%	-72.8%	-52.0%	-11.1%	-15.2%	-2.4%	0.03×	0.55×	0×	11.34×	0.0%	1	14.74	2	C
IMNMImmunome, Inc.	$18.96	-8.84×	2.96×	270.32×	-5.86×	-62.3%	57.4%	-3084.8%	-3060.0%	-33.5%	-33.5%	-10.7%	0.01×	3.1×	0×	14.69×	0.0%	2	31.88	2	C+
Peer median	—	-4.66×	2.52×	11.39×	-4.38×	-92.2%	57.4%	-290.7%	-292.1%	-40.9%	-33.5%	-20.8%	0.01×	0.55×	0×	11.34×	0.0%	2	12.15	2	—